Global 2021 sales grew +18% year-over-year to €7.7M Mauna Kea Technologies announced fourth quarter and full year 2021 sales. Total...
Mauna Kea Technologies Reports Fourth Quarter and Full Year 2021 Sales
read more
Search Results
Mauna Kea Technologies Provides Business Update
Corporate resources focused on highest value clinical applications Significant reduction in operating expenses implemented Cash runway now extended...
Mauna Kea Technologies Announces Strategic Realignment
Company to focus resources on robotic assisted interventional pulmonology and molecular imaging Nicolas Bouvier, member of the Executive Committee,...
Mauna Kea Technologies Announces a New Publication Demonstrating the Economic Benefit of Cellvizio® for Pancreatic Cyst Management
Proven diagnostic accuracy of Cellvizio allows for successful downstaging of non-mucinous lesions and prevention of unnecessary surgeries, resulting...
Mauna Kea Technologies reports third quarter and first nine months of 2021 sales
Mauna Kea Technologie announced third quarter and first nine months of 2021 sales results for the periods ended September 30, 2021. First...
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the ERS International Congress 2021
Further validation of how Cellvizio is a complementary technology to manual and robotic-assisted bronchoscopy, potentially impacting patient...
Mauna Kea Technologies reports first half 2021 financial results
Mauna Kea Technologies today announced first half 2021 financial results for the six months ended June 30, 2021. First Half 2021 Financial...
Mauna Kea Technologies Announces New Clinical Study and Research Collaboration Agreement with the Lung Cancer Initiative at Johnson & Johnson
Mauna Kea Technologies (the “Company”), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal...
Mauna Kea Technologies announces a capital increase of approximately €12.5 million reserved for two investors
This transaction by issuance of Units allows the Company to secure its financing until the end of the third quarter of 2022 Mauna Kea...
Mauna Kea Technologies Receives U.S. FDA 510(k) Clearance of its Next-Generation Cellvizio® Platform Combined with a Fluorescent Contrast Agent
The next-generation Cellvizio® platform is now cleared for use with fluorescein dye to image blood flow in the microvasculature and capillaries...
Mauna Kea Technologies Reports Second Quarter and First Half of 2021 Sales
Mauna Kea Technologies today announced second quarter and first half 2021 sales results for the three and six-month periods ended June 30,...
Mauna Kea Technologies Announces Completion of Enrollment of the First in Human Clinical Study Combining Robotic-Assisted Bronchoscopy and Needle-Based Confocal Laser Endomicroscopy
The study combining Cellvizio® with the AQ-Flex™ 19 Confocal Miniprobe™ and the Monarch® Platform from Auris Health, Inc.,...